Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2011 Jun;34(3):789-93.
doi: 10.1007/s10545-011-9307-7. Epub 2011 Mar 23.

Gaucher disease: when molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S)--RecNcil allele

Affiliations
Case Reports

Gaucher disease: when molecular testing and clinical presentation disagree -the novel c.1226A>G(p.N370S)--RecNcil allele

Manisha Balwani et al. J Inherit Metab Dis. 2011 Jun.

Abstract

We report a 31 year old woman who had prenatal carrier screening for Ashkenazi Jewish (AJ) genetic diseases and was found to have two acid ß-glucosidase (GBA) mutations, c.1226A>G(p.N370S) and c.1448T>C(p.L444P), consistent with the diagnosis of Type 1 Gaucher disease (GD1). This genotype typically manifests in late-adolescence with hepatosplenomegaly and early-onset bone involvement. The Proband had a normal physical examination, no organomegaly, and normal blood counts, skeletal survey, and bone density. Leukocyte acid ß-glucosidase and plasma chitotriosidase activities were normal. To investigate these unexpected results, her GBA alleles were RT-PCR amplified and sequenced. Five RT-PCR clones were negative for both mutations, while five clones had the c.1226A>G(p.N370S) and c.1448T>C(p.L444P) mutations, along with c.1483G>C(p.A456P), and c.1497G>C(p.V460V) mutations, the latter three lesions composing the rare GBA pseudogene-derived RecNcil allele. Genetic testing misdiagnosed the asymptomatic Proband as affected with Type 1 Gaucher disease; however, molecular studies revealed a novel allele with the two common GBA mutations on the RecNcil background. This allele presumably arose by crossing-over between a c.1226A>G allele and the pseudogene, gene conversion, or a new c.1226A>G mutation on the RecNcil background. This novel complex allele highlights a limitation of carrier screening for GD.

PubMed Disclaimer

Conflict of interest statement

A competing interest statement RJD is a consultant to, and receives research and training grants from, the Genzyme Corporation, and has founder shares in Amicus Therapeutics, Inc. Mount Sinai school of Medicine, the Department of Genetics and Genomic Sciences and some faculty members in the department (including the Chair and Dean for Genetics and Genomics, Dr. Robert Desnick) receive financial benefit from the Genzyme Corporation for the sale of Fabrazyme®, an enzyme replacement drug developed by them for the treatment of Fabry disease. MB is a member of the ICGG North American advisory board and has received an honorarium from Genzyme. Other authors declare no competing interests.

References

    1. Aerts JM, Hollak CE, van Breemen M, Maas M, Groener JE, Boot RG. Identification and use of biomarkers in Gaucher disease and other lysosomal storage diseases. Acta Paediatr Suppl. 2005;94:43–46. - PubMed
    1. Balwani M, Fuerstman L, Kornreich R, Edelmann L, Desnick RJ. Type I Gaucher disease: Significant disease manifestations in “asymptomatic” homozygotes. Arch Intern Med. 2010;170:1463–1469. - PMC - PubMed
    1. Beutler E, Liebman H, Gelbart T, Stefanski E. Three Gaucher-disease-producing mutations in a patient with Gaucher disease: mechanism and diagnostic implications. Acta Haematol. 2000;104:103–105. - PubMed
    1. Eng CM, Schechter C, Robinowitz J, et al. Prenatal genetic carrier testing using triple disease screening. JAMA. 1997;278:1268–1272. - PubMed
    1. Eyal N, Wilder S, Horowitz M. Prevalent and rare mutations among Gaucher patients. Gene. 1990;96:277–283. - PubMed

Publication types

Substances